

General index

GENERAL INTRODUCTION.....	2
1. NANOTECHNOLOGY AND NANOMEDICINE.....	3
2. MESOPOROUS SILICA MATERIALS.....	6
2.1. <i>Synthesis of mesoporous silica materials.....</i>	<i>7</i>
2.2. <i>Functionalisation of mesoporous silica materials.....</i>	<i>8</i>
2.3. <i>Characterization.....</i>	<i>9</i>
2.4. <i>Stimuli-responsive gated materials.....</i>	<i>12</i>
3. JANUS NANOPARTICLES.....	14
4. MESOPOROUS HYBRID MATERIALS FOR BIOMEDICAL APPLICATIONS.....	17
4.1. <i>Cell uptake, biocompatibility and biodistribution of hybrid nanoparticles.....</i>	<i>17</i>
4.1.1. MSNs.....	18
4.1.2. Gold nanoparticles.....	21
4.1.3. Platinum nanoparticles.....	23
4.2. <i>Clinical relevance of hybrid mesoporous silica nanoparticles.....</i>	<i>24</i>
5. NANOMEDICINE FOR CANCER THERAPY.....	27
6. NANOMOTORS.....	30
7. NANOTECHNOLOGY FOR IMPROVING CANCER IMMUNOTHERAPY.....	35
7.1. <i>Immune evasion and main strategies in cancer immunotherapy.....</i>	<i>35</i>
7.2. <i>Nanoparticles-based approaches.....</i>	<i>41</i>
8. REFERENCES.....	45
OBJECTIVES.....	63
CHAPTER I STIMULUS-RESPONSIVE NANOMOTORS BASED ON GATED ENZYME- POWERED JANUS AU-MESOPOROUS SILICA NANOPARTICLES FOR ENHANCED CARGO DELIVERY.....	67
1. ABSTRACT.....	71
2. INTRODUCTION.....	71

3.	RESULTS AND DISCUSSION.....	73
4.	CONCLUSIONS.....	79
5.	MATERIALS AND METHODS.....	80
5.1.	<i>Chemicals</i>	80
5.2.	<i>General methods</i>	80
5.3.	<i>Synthesis of mesoporous silica nanoparticles (MSNs)</i>	81
5.4.	<i>Synthesis of gold nanoparticles (AuNPs)</i>	81
5.5.	<i>Synthesis of Janus Au-MSNs (S0)</i>	82
5.6.	<i>Synthesis of gated nanoparticles S1</i>	82
5.7.	<i>Preparation of enzyme-functionalized gated nanoparticles (S1cat)</i>	83
5.8.	<i>Preparation of S1dox-cat</i>	83
5.9.	<i>Catalase activity</i>	84
5.10.	<i>Motion analysis</i>	85
5.11.	<i>Release experiments</i>	86
5.12.	<i>Experiments with Hela cells</i>	86
5.12.1.	<i>Cell culture conditions</i>	86
5.12.2.	<i>Confocal microscopy studies of doxorubicin controlled release</i>	87
6.	REFERENCES.....	87
7.	SUPPORTING INFORMATION.....	91
7.1.	<i>Materials characterization</i>	91
7.2.	<i>Motion analysis</i>	94
7.3.	<i>Release experiments</i>	95

CHAPTER II | ULTRA-FAST DIRECTIONAL JANUS PT-MESOPOROUS SILICA NANOMOTORS FOR SMART DRUG DELIVERY.....97

1.	ABSTRACT.....	101
2.	INTRODUCTION.....	102

3.	RESULTS AND DISCUSSION.....	105
3.1.	<i>Nanomotors synthesis and characterization.....</i>	105
3.2.	<i>Motion analysis.....</i>	109
3.3.	<i>Control Release Studies.....</i>	113
3.4.	<i>Self-propel and drug release capabilities in cells.....</i>	115
4.	CONCLUSIONS.....	121
5.	MATERIALS AND METHODS.....	122
5.1.	<i>Chemicals.....</i>	122
5.2.	<i>General methods.....</i>	123
5.3.	<i>Synthesis of mesoporous silica nanoparticles (MSNs).....</i>	123
5.4.	<i>Synthesis of platinum nanodendrites (PtNds).....</i>	124
5.5.	<i>Synthesis of Janus Pt-MSN nanoparticles (S0).....</i>	124
5.6.	<i>Synthesis of Janus Pt-MSN (Ru)-PEG (S1).....</i>	124
5.7.	<i>Synthesis of Janus Pt-MSN (Doxorubicin)-PEG (S2).....</i>	125
5.8.	<i>Peroxidase-like activity assay.....</i>	125
5.9.	<i>Motion analysis by MSD calculation.....</i>	126
5.10.	<i>Control release studies.....</i>	127
5.11.	<i>Cell culture conditions.....</i>	128
5.12.	<i>Viability Assay.....</i>	128
5.13.	<i>Cell uptake of nanomotors by confocal microscopy.....</i>	129
5.14.	<i>Cell uptake of nanomotors by TEM.....</i>	129
5.15.	<i>Self-propel and drug release capabilities of S2 in microchip device.....</i>	129
6.	REFERENCES.....	130
7.	SUPPORTING INFORMATION.....	142
7.1.	<i>Nanomaterial characterization.....</i>	144
7.1.1.	<i>Powder X-ray diffraction analysis.....</i>	145

7.1.2.	N ₂ adsorption-desorption isotherms.....	145
7.1.3.	Thermogravimetric assay.....	147
7.1.4.	DLS analysis.....	148
7.2.	<i>Motion analysis</i>	148
7.2.1.	Peroxidase-like activity assay.....	148
7.3.	<i>Control release studies</i>	151
7.4.	<i>Cell assays</i>	151

CHAPTER III | NANOPARTICLE-MEDIATED TUMOR MICROENVIRONMENT REMODELING FAVORS THE COMMUNICATION WITH THE IMMUNE CELLS FOR TUMOR KILLING.....153

1.	ABSTRACT.....	157
2.	INTRODUCTION.....	157
3.	RESULTS AND DISCUSSION.....	162
3.1.	<i>Design, synthesis, and characterization of nanodevices</i>	162
3.2.	<i>MSN(JQ1)-PEI-siRNA nanoparticles are efficiently internalized with the subsequent siRNA delivery</i>	165
3.3.	<i>MSNs as a versatile nanosystem for the codelivery of JQ-1 and TGF-β siRNA</i>	167
3.4.	<i>The codelivery of JQ-1 and TGF-β restores cancer cell death</i>	170
4.	CONCLUSIONS.....	172
5.	MATERIALS AND METHODS.....	173
5.1.	<i>General methods</i>	173
5.2.	<i>Synthesis of MSNs MCM-41 type</i>	173
5.3.	<i>Preparation of MSN(JQ1)-PEI and MSN-PEI nanoparticles</i>	174
5.4.	<i>Quantification of JQ1 delivered</i>	174
5.5.	<i>Assembly optimization of TGF-β siRNA to PEI-coated MSNs</i>	175
5.6.	<i>Synthesis of MSN(JQ1)-PEI-siRNA, MSN-PEI-siRNA, and MSN(JQ1)-PEI-BlockiT...</i>	175
5.7.	<i>Cell culture conditions</i>	175

5.8.	<i>Toxicity studies</i>	176
5.9.	<i>Endosomal escape</i>	176
5.10.	<i>Evaluation of PD-L1 expression by Western Blot</i>	177
5.11.	<i>Flow cytometric determination of PD-L1 expression</i>	177
5.12.	<i>Silencing assay</i>	178
5.13.	<i>Evaluation of T-cell-mediated killing of melanoma cells</i>	178
5.14.	<i>Statistical analysis</i>	179
6.	REFERENCES.....	179
7.	SUPPORTING INFORMATION.....	188

CHAPTER IV | NANOPARTICLES TO RE-ESTABLISH COMMUNICATION BETWEEN CANCER AND IMMUNE CELLS AS A NEW IMMUNOTHERAPEUTIC STRATEGY.....195

1.	ABSTRACT.....	199
2.	INTRODUCTION.....	199
3.	RESULTS AND DISCUSSION.....	202
3.1.	<i>Design, synthesis, and characterization of nanoparticles</i>	202
3.2.	<i>J-pHLIP-PD1 nanoparticles attach to cancer cell membrane and capture of T-lymphocytes</i>	206
3.3.	<i>Cellular communication and therapeutic effect of J-pHLIP-PD1</i>	210
3.4.	<i>J-pHLP-PD1 reduces metastatic clusters in a B16-F10-Luc mouse metastatic model</i>	211
4.	CONCLUSIONS.....	215
5.	MATERIALS AND METHODS.....	216
5.1.	<i>General Techniques</i>	216
5.2.	<i>Synthesis of mesoporous silica nanoparticles</i>	217
5.3.	<i>Synthesis of gold nanoparticles</i>	217
5.4.	<i>Synthesis of Janus MSN-Au nanoparticles</i>	218
5.5.	<i>Synthesis of RBITC-APTES dye derivative</i>	218
5.6.	<i>Synthesis of J*-pHLIP and J-pHLIP</i>	219

5.7.	<i>Preparation of J-PD1, J*-pHLIP-PD1 and J-pHLIP-PD1 nanoparticles.....</i>	219
5.8.	<i>Cell culture conditions.....</i>	220
5.9.	<i>Evaluation of PD-1 expression by Western Blot.....</i>	220
5.10.	<i>Flow cytometric determination of PD-1 expression.....</i>	221
5.11.	<i>Evaluation of nanoparticle attachment to cell membrane.....</i>	221
5.12.	<i>Lymphocytes migration and retention assay.....</i>	222
5.13.	<i>Evaluation of therapeutic effect in cocultures.....</i>	222
5.14.	<i>B16-F10-Luc Metastatic Model.....</i>	223
5.15.	<i>Histological analysis of lungs for metastasis evaluation.....</i>	223
5.16.	<i>Isolation and immunophenotyping of plasma cells from ex vivo lungs of mice...</i>	224
5.17.	<i>Statistical analysis.....</i>	224
6.	REFERENCES.....	225
7.	SUPPORTING INFORMATION.....	233
	DISCUSSION.....	239
	CONCLUSIONS.....	247